GLPwatch
Papers (10401)
Page 56 of 174, ranked by citation count.
- Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
- Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling.
- Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons.
- Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.
- Once weekly exenatide: efficacy, tolerability and place in therapy.
- Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
- Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
- Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
- Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
- The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
- Effects of liraglutide on β-cell-specific glucokinase-deficient neonatal mice.
- Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.
- Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.
- Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.
- Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
- Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.
- Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord.
- Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
- Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
- Eosinophil-rich granulomatous panniculitis caused by exenatide injection.
- Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
- Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
- US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.
- Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
- Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
- DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
- The role of GLP-1/GIP receptor agonists in Alzheimer's disease.
- Clinical review of subcutaneous semaglutide for obesity.
- Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
- The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
- PET of glucagonlike peptide receptor upregulation after myocardial ischemia or reperfusion injury.
- A GLP-1/glucagon (GCG)/CCK<sub>2</sub> receptors tri-agonist provides new therapy for obesity and diabetes.
- Dapagliflozin and Liraglutide Therapies Rapidly Enhanced Bone Material Properties and Matrix Biomechanics at Bone Formation Site in a Type 2 Diabetic Mouse Model.
- Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE <sup>-/-</sup> mice.
- Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
- Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
- Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells.
- Long-Term Exposure of Pancreatic β-Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response.
- The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.
- Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
- Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model.
- GLP-1 and the Neurobiology of Eating Control: Recent Advances.
- Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.
- Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials.
- Disruption of CR6-interacting factor-1 (CRIF1) in mouse islet beta cells leads to mitochondrial diabetes with progressive beta cell failure.
- Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
- Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.
- Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.
- Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.
- Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.
- Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.
- Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
- Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.
- Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
- Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice.
- Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure.
- Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes.